Cost per responder for upadacitinib vs abatacept in pati ents with moderate-to-severe Rheumatoid Arthritis in Italy (vol 8, pg 69, 2021)

被引：0
|
作者：
Caporali, Roberto [1 ,2 ]
Ravasio, Roberto [3 ]
Raimondo, Paola [3 ]
Salaffi, Fausto [4 ]
机构：
[1] Univ Milan, Dept Clin & Community Sci DISCCO, Milan, Italy
[2] ASST Pini COT, Dept Rheumatol & Med Sci, Milan, Italy
[3] Market Access Provider, Milan, Italy
[4] Univ Politecn Marche, Carlo Urbani Hosp, Dept Clin & Mol Sci, Rheumatol Clin, Jesi, AN, Italy
来源：
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT | 2022年 / 9卷
关键词：
D O I：
10.33393/grhta.2022.2383
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：30 / 30
页数：1
相关论文
共 24 条
  • [1] Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
    Caporali, Roberto
    Ravasio, Roberto
    Raimondo, Paola
    Salaffi, Fausto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 69 - 79
  • [2] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [3] Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
    Gisondi, Paolo
    Loconsole, Francesco
    Raimondo, Paola
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 120 - 130
  • [4] Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China
    Xu, Xinyi
    Geng, Linyu
    Xu, Xue
    Huang, Saisai
    Liang, Jun
    IMMUNOTHERAPY, 2024,
  • [5] Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy
    Stingeni, Luca
    Ravasio, Roberto
    Palladino, Chiara
    Di Fino, Sara
    Levi, Anna
    Ronci, Gianluca
    Gisondi, Paolo
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2025, 12 : 70 - 79
  • [6] ADVERSE EVENT-RELATED COSTS ASSOCIATED WITH ABATACEPT AND UPADACITINIB FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS
    Han, X.
    Park, S. H.
    Schmier, J. K.
    Ning, N.
    Patel, D.
    Kakehi, S.
    VALUE IN HEALTH, 2021, 24 : S139 - S139
  • [7] Drug cost per responder for the treatment of moderate-to-severe psoriasis and active psoriatic arthritis
    Armstrong, April
    Merola, Joseph
    Yang, Min
    Li, Junlong
    Zhao, Jing
    Sundaram, Murali
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB105 - AB105
  • [8] Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan
    Atsumi, Tatsuya
    Asakura, Eri
    Doi, Michio
    Sawant, Ruta
    Kawaguchi, Isao
    Sasaki, Nobuhito
    Liew, Danny
    MODERN RHEUMATOLOGY, 2023, 33 (01) : 54 - 63
  • [9] Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy
    Pompilio, Giuseppe
    Integlia, Davide
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2022, 9 : 138 - 145
  • [10] Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy
    Ravasio, Roberto
    Antonelli, Silvia
    Maiorino, Alessia
    Costanzo, Antonio
    Losi, Serena
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2019,
123